ClinicalTrials.gg
CompletedNCT04256083AMNIOPROFILUpdated Jul 8, 2022

Metabolomic and Proteomic Profiles of Amniotic Fluid Embolism

An observational study in Amniotic Fluid Embolism, sponsored by Hospices Civils de Lyon. Completed at 4 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-08.

Sponsored by Hospices Civils de Lyon · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
18 Years and older
Sex
Female
01

Study summary

Amniotic fluid embolism is a serious complication of the peri-partum period that is associated with high maternal mortality rate, ranging from 20 to 40%.

The pathophysiology of amniotic fluid embolism remains poorly known at this time.

The definition and diagnosis of amniotic fluid embolism is only clinical, based on different scores, the most used of which is the score proposed by the United Kingdom Obstetric Surveillance System (UKOSS). This score supports the diagnosis of amniotic fluid embolism in the event of acute maternal collapse associated with one or more of the following features: cardiac rhythm problems, acute fetal compromise, respiratory distress, maternal hemorrhage, coagulopathy, convulsions, premonitory symptoms (restlessness, numbness, tingling, agitation, etc.). ) seizure, in the absence of any other clear cause. Amniotic fluid embolism is a differential diagnosis of maternal collapse.

Determining specific biological markers for this disease would be very useful in order to be able to affirm the diagnosis and refute other diagnostic hypotheses with certainty. The detection of amniotic cells in the blood or bronchoalveolar lavage fluid seems to be of little help. The assay of plasma tryptase does not confirm the diagnosis of amniotic embolism, but is useful for ruling out the diagnosis of anaphylactic shock. The dosage of the complement lacks sensitivity and specificity to be useful in the diagnosis of amniotic fluid embolism. The maternal plasma assay of IGFBP-1 ("Insulin Growth Factor Binding Protein" type 1) has been proposed for the biological diagnosis of amniotic embolism. IGFBP-1 is present in high concentration in amniotic fluid, while its concentration is low in maternal plasma. High levels of IGFBP-1 in maternal blood would therefore make it possible to establish the diagnosis of amniotic fluid embolism with excellent sensitivity and specificity according to previous data collected from 25 patients. However, no study has confirmed this result to date. Other markers have also been suggested (zinc-coproporphyrin in particular), but to date, no specific marker for this disease has been formally identified.

Metabolic phenotyping consists in the identification of subtle and coordinated metabolic variations associated with various pathophysiological stimuli. Different analytical methods, such as nuclear magnetic resonance, allow the simultaneous quantification of a large number of metabolites. Statistical analyses of these spectra thus lead to the discrimination between samples and the identification of a metabolic phenotype corresponding to the effect under study. This approach allows the extraction of candidate biomarkers and the recovery of perturbed metabolic networks, driving to the generation of biochemical hypotheses (pathophysiological mechanisms, diagnostic tests, therapeutic targets,...).. It is thus possible to obtain biochemical characterizations of human biological samples (also called "metabolic profile or signature") which can be compared in order to identify distinctive elements of certain pathophysiological states, establishing a metabolic phenotype of the pathological state studied. This analysis can be supplemented by a study of the proteome (proteomics), in order to identify one or more biological markers associated with a disease.

The aim of this study is to determine the metabolic and proteomic phenotyping in three groups of women: women for whom the diagnosis of amniotic fluid embolism was retained according to the UKOSS clinical criteria (Group AFE), women admitted for prophylactic elective cesarean section (Group Control 1), women presenting acute collapse or shock in the peri- partum for which the diagnosis of amniotic fluid embolism has been excluded (severe hemorrhage, SEPSIS, pulmonary embolism for example; Group Control 2)

02

Conditions studied

  • Amniotic Fluid Embolism
03

In context

Lead sponsor

Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 447 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will focus on women with clinical criteria for amniotic embolism for whom the samples were sent to the fetal-maternal biology laboratory of Hospices Civils de Lyon (HCL), women with peri-partum collapse for which the diagnosis of amniotic embolism is excluded, and women admitted to term for a scheduled cesarean.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Group AFE

    • adult women
    • presenting the diagnostic criteria for amniotic embolism according to the UKOSS initiative,
    • having no known notable medical history (class of the 1)
    • and whose samples were taken within the first 6 hours of collapse and were sent to the fetal-maternal biology laboratory of the Hospices Civils de Lyon (HCL).
  • Group Control 1

    • term adult women
    • admitted for scheduled caesarean, term (> 38 weeks), without pathology or associated medical history (class of the American Society of Anesthesiologists 1),
    • biological sample planned before the cesarean section (search for irregular agglutinins).
  • Group Control 2:

    • term adult women (> 38 weeks)
    • presenting a collapse (systolic blood pressure \<80 mmHg twice and for> 5 minutes) or acute peri-partum shock, for which the diagnosis of amniotic embolism is not retained,
    • no known notable medical history (class of the American Society of Anesthesiologists 1),
    • sampling taken within the first 6 hours of the shock or collapse.

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate
  • birth as part of an intrauterine fetal death or a therapeutic termination of pregnancy
  • preeclampsia, eclampsia
  • Gestational Diabetes
  • any known endocrine pathology (diabetes, dysthyroidism, adrenal insufficiency, pituitary and hypothalamic diseases).
  • history of disease
  • rate \<7 g / dl at the time of sampling (Control group 1 and 2)
  • major protected (guardianship, curatorship) or placed under judicial protection
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (actual)
Patient registry
No

Groups and cohorts

  • AFE (amniotic fluid embolism)

    Women for whom the diagnosis of amniotic fluid embolism was retained according to the UKOSS criteria.

    Biological: Biological analysis

  • Control 1

    Women admitted for prophylactic elective cesarean section.

    Biological: Biological analysis

  • Control 2

    Women with acute collapse in the peripartum period (with systolic blood pressure \<80 mmHg twice and for\> 5 minutes or acute peri-partum shock, for which the diagnosis of amniotic embolism has been ruled out).

    Biological: Biological analysis

Interventions

  • BiologicalBiological analysis

    Two blood samples of 4 ml each (total: 8 ml) for IGFBP1 assay and metabolic phenotyping and proteomic analysis.

06

What researchers measure

Primary outcomes

  1. Metabolic phenotyping of amniotic fluid embolism

    Metabolic phenotyping consists in the identification of subtle and coordinated metabolic variations associated with various pathophysiological stimuli. Different analytical methods, such as nuclear magnetic resonance, allow the simultaneous quantification of a large number of metabolites. Statistical analyses of these spectra thus lead to the discrimination between samples and the identification of a metabolic phenotype corresponding to the effect under study. Blood sample taken within the first 6 hours of collapse (Groups AFE and Control 2) and prior patient arrival in the operating room (Group Control1)

    Time frame: 6 hours

  2. Proteomic analysis of amniotic fluid embolism

    Study of the proteome (proteomics), in order to identify one or more biological markers associated with a disease. Blood sample taken within the first 6 hours of collapse (Groups AFE and Control 2) and prior patient arrival in the operating room (Group Control1)

    Time frame: 6 hours

07

Study locations

4 sites
  • Service Anesthésie réanimation - Centre Hospitalier Hôpital Femme Mère Enfant - Groupement Hospitalier Est - Hospices Civils de Lyon
    Bron, 69500, France
  • Service d'anesthésie réanimation Hôpital de la Croix Rousse
    Lyon, 69004, France
  • Service d'anesthésie réanimation Centre Hospitalier Lyon-Sud
    Pierre-Bénite, 69310, France
  • Service Anesthésie Réanimation CHU de Hautepierre, Strasbourg
    Strasbourg, 67000, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Oct 2021, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2020
First posted
Feb 5, 2020
StartActual
Jun 24, 2021
Primary completionActual
Oct 25, 2021
CompletionActual
Oct 25, 2021
Last update
Jul 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04256083
Responsible party
Sponsor
First posted
Feb 5, 2020
Start date
Jun 24, 2021
Primary completion
Oct 25, 2021
Completion
Oct 25, 2021
Last update
Jul 8, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion